• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Culture May suck but the stock is hot!





This is the short sided, poor leadership HQ has been demonstrating. All sins are forgiven when the stock is strong. It doesn’t have to be one or the other and should actually be both.We have good fortune that our science is strong and our products are better. Just think of how much higher the stock could be if Langa wasn’t driving!

Lars, now is the time to make a move. Fix the roof when the sun is shining!
 




This is the short sided stupidity within Novo. No one here seems to understand the concept of missed opportunity. If our leadership and middle managers were anywhere near as good as our science we'd be what Apple of pharma. We'd make even more in stock, have the best talent here and so on..well enjoy the cash for now. Maybe you could add some diamonds to those golden shackles.

My Novo stock has doubled!
 












This is the short sided, poor leadership HQ has been demonstrating. All sins are forgiven when the stock is strong. It doesn’t have to be one or the other and should actually be both.We have good fortune that our science is strong and our products are better. Just think of how much higher the stock could be if Langa wasn’t driving!

Lars, now is the time to make a move. Fix the roof when the sun is shining!

Langa and Doustdar - two absolutely hopeless idiots!
The stock is high due to market forces (so much liquidity) and has nothing to do with the performance of NN and especially these two hopeless individuals.
 








Between developing semaglutide to do it all and acquiring dicerna the R and D side does all the heavy lifting to get sellable products that doctors want to use. They keep us alive.
The leadership across the entire org ruins everything else after that.
 




Between developing semaglutide to do it all and acquiring dicerna the R and D side does all the heavy lifting to get sellable products that doctors want to use. They keep us alive.
The leadership across the entire org ruins everything else after that.

Sema failed NASH study…suppose that’s Sales’ fault also?
 




This is the short sided stupidity within Novo. No one here seems to understand the concept of missed opportunity. If our leadership and middle managers were anywhere near as good as our science we'd be what Apple of pharma. We'd make even more in stock, have the best talent here and so on..well enjoy the cash for now. Maybe you could add some diamonds to those golden shackles.

My Novo stock has doubled![/QUOTE

The stock is up because the company is repurchasing its own shares and has been for the last 18 months.

My god, you are all incompetent. No wonder they want to have another layoff.

https://finance.yahoo.com/news/novo-nordisk-share-repurchase-programme-140900396.html